Rocuronium Bromide

CHEMBL1200648 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
609.7 g/mol
LogP
Phase
4

A bromide salt form of rocuronium with the same therapeutic properties. A neuromuscular blocking agent used during surgery and intubation to produce muscle relaxation by blocking acetylcholine receptors at the neuromuscular junction.

Masse moléculaire

609,7000 g/mol

TPSA

59,00 Ų

Aires thérapeutiques

Mécanisme d'action

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1.[Br-]

InChI

InChI=1S/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1

Molecular Formula

C32H53BrN2O4

HBD / HBA

1 / 6

Liaisons Rotatives

6

Atomes Lourds

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A bromide salt form of rocuronium with the same therapeutic properties. A neuromuscular blocking agent used during surgery and intubation to produce muscle relaxation by blocking acetylcholine receptors at the neuromuscular junction.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Rocuronium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200648. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 441351. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.